Full Press Release Details
BiondVax Announces Pricing of $9.0 million Follow-on
Underwritten Offering of American Depositary Shares
Jerusalem, Israel - December 27, 2021
- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing
innovative products for the prevention and treatment of infectious diseases and other illnesses, today announced the pricing of an underwritten
public offering of 3,813,560 American Depositary Shares ("ADSs") at a public offering price of $2.36 per ADS for gross proceeds
to the Company of approximately $9.0 million, before deducting underwriting discounts and other offering expenses. Each ADS represents
40 ordinary shares of BiondVax.
BiondVax intends to use the net proceeds
from this offering for the advancement of its recently announced nanosized antibody (NanoAb) development program as well as for general
corporate purposes, including, but not limited to, working capital, research and development activities, regulatory matters, capital investment
or other related purposes. It may also use a portion of any net proceeds to in-license, invest in or acquire businesses, assets or technologies
that it believes are complementary to its business focus, although it has no current commitments or agreements in those regards.
The offering is expected to close on or about
December 29, 2021, subject to customary closing conditions. In connection with the offering, the Company has also granted the underwriters
a 45-day option to purchase additional ADSs offered to the public at the public offering price, less underwriting discount, for covering
over-allotments, if any. If the over-allotment option is exercised in full it would increase the total gross proceeds of the offering
to approximately $9.8 million.
Aegis Capital Corp. is acting as the sole
book-running manager for the offering.
The ADS described above are being offered
by the Company pursuant to a "shelf" registration statement on Form F-3 (333-240189) filed with the Securities and Exchange
Commission (the "SEC") and declared effective by the SEC on August 10, 2020. An electronic preliminary prospectus supplement
and the accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC's website at www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from Aegis
Capital Corp., Attention: Syndicate Department, 810 7th Avenue, 18th Floor, New York, NY 10019, by email at syndicate@aegiscap.com, or
by telephone at (212) 813-1010. A final prospectus supplement and accompanying base prospectus describing the final terms of the offering
will be filed with the SEC and, when available, may be obtained by accessing the SEC's website or by contacting Aegis Capital Corp.
at the phone number and email address listed in the previous sentence.
Before buying any of the BiondVax ADSs, investors
should read the preliminary prospectus supplement and accompanying prospectus and other documents incorporated by reference therein, available
on the SEC's website, for more complete information about the Company and this offering.
This press release shall not constitute an
offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities
laws of any such jurisdiction.
Jerusalem BioPark, 2nd floor Hadassah Ein Kerem Campus Jerusalem, Israel
Telephone: +972-8-9302529 Fax: +972-8-9302531 www.BiondVax.com
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV)
is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment
of infectious diseases and other illnesses. Since its inception, the company has executed eight clinical trials including a seven country,
12,400 participant Phase 3 trial of its vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical
products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially
viable products and platforms, beginning with an innovative nanosized antibody (NanoAb) pipeline. For more information, please visit www.biondvax.com.
Company: Joshua E. Phillipson | +972 8 930 2529 |
Investor Relations: Kenny Green | +1 212 378 8040
Forward Looking Statements
The Private Securities Litigation Reform Act of 1995
provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute
"forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, including but not limited to statements regarding BiondVax's ability to complete the offering, expected gross
proceeds, expected closing date of the offering and the expected use of the proceeds from the offering. Any statement that is not historical
in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates,"
"believes," "will," "will likely result," "will continue," "plans to," "potential,"
"promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject
to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking
statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with
the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected.
BiondVax undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events,
or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that
may affect future results and that the risks described herein should not be considered a complete list.
Jerusalem BioPark, 2nd floor Hadassah Ein Kerem Campus Jerusalem, Israel
Telephone: +972-8-9302529 Fax: +972-8-9302531 www.BiondVax.com